All In Biotech

Drug Trial Radar · NCT02992743

Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

A Pilot Study of NY-ESO-1c259T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma

Last checked: Nov 20, 2026Latest source record: Apr 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

23

Actual

Start

Dec 6, 2016

Primary completion

Nov 1, 2021

Study completion Mar 22, 2022

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Dec 14, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will evaluate safety and efficacy of Letetresgene autoleucel (GSK3377794) in participants with advanced myxoid/round cell liposarcoma or high-grade myxoid liposarcoma.

Conditions

  • Neoplasms

Interventions

  • letetresgene autoleucel (GSK3377794)Drug

    Letetresgene autoleucel (GSK3377794) as an IV infusion.

  • CyclophosphamideDrug

    Cyclophosphamide will be used as a lymphodepleting chemotherapy.

  • FludarabineDrug

    Fludarabine will be used as a lymphodepleting chemotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator AssessmentTime frame: Up to 24 months
  2. Best Overall Response (BOR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator AssessmentTime frame: Up to 24 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Ann Arbor, Michigan

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Columbus, Ohio

  • GSK Investigational Site

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.